Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vector-based therapies can effectively correct some disease pathology in murine models with mucopolysaccharidoses. However, immunogenicity can limit therapeutic effect as immune responses target capsid proteins, transduced cells, and gene therapy products, ultimately resulting in loss of enzyme activity. Inherent differences in male versus female immune response can significantly impact AAV gene transfer. We aim to investigate sex differences in the immune response to AAV gene therapies in mice with mucopolysaccharidosis IVA (MPS IVA). MPS IVA mice, treated with different AAV vectors expressing human N-acetylgalactosamine 6-sulfate sulfatase (GALNS), demonstrated a more robust antibody response in female mice resulting in subsequent decreased GALNS enzyme activity and less therapeutic efficacy in tissue pathology relative to male mice. Under thyroxine-binding globulin promoter, neutralizing antibody titers in female mice were approximately 4.6-fold higher than in male mice, with GALNS enzyme activity levels approximately 6.8-fold lower. Overall, male mice treated with AAV-based gene therapy showed pathological improvement in the femur and tibial growth plates, ligaments, and articular cartilage as determined by contrasting differences in pathology scores compared to females. Cardiac histology revealed a failure to normalize vacuolation in females, in contrast, to complete correction in male mice. These findings promote the need for further determination of sex-based differences in response to AAV-mediated gene therapy related to developing treatments for MPS IVA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Cassette and study design. The experimental scheme of the first study was described by Sawamoto et al. [23]. AAV8: adeno-associated virus 8, ITR: inverted terminal repeat, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, D8: aspartic acid octapeptide, hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, RBG pA: rabbit β globin poly-A tail.](https://figures.cochat.ai/paper-figures/906c9366651941619f6f6339dcc55566/sex-difference-leads-to-differential-gene-expression-patterns-and-therapeutic-figure-1.jpg)








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may lead to a stronger adaptive response in AAV gene therapy in females with greater cell and antibody-mediated immunity directed against the transgene product resulting in poorer treatment durability (Piechnik et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Piechnik et al., 2022
Experimental — accuracy not yet measuredIn the citing paper
“Sex differences in transgene expression have been observed in pre-clinical studies with AAV delivery to liver or systemically,59,60 with females showing lower levels of transgene expression, linked to both sex hormones59 and a more robust humoral immune response in females.60”
From Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age (2025) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370 · cited 3×
“In mammals, females have been shown to mount more robust immune responses, innate and adaptive, compared to males [26].”
BackgroundInfluentialAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“Several strategies have been employed to overcome the immune response, including liver targeting to induce immune tolerance [17,18] and the use of steroids to inhibit T cell responses against the capsid to provide durable transgene expression [18,19] being the most well-known methods in clinical and preclinical models…”
MethodAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“AAV has been shown to efficiently transduce target cells, induce high enzyme activity levels in target tissues, and achieve sustainable long-term enzyme expression [12,13].”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Rettew, J. A., Huet-Hudson, Y. M., & Marriott, I. (2008) · Biology of Reproduction · doi:10.1095/biolreprod.107.063545 · Cited by 376
Sugimoto, C. R., Ahn, Y.-Y., Smith, E., Macaluso, B., & Larivière, V. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32995-7 · Cited by 305
Cited by
A comprehensive atlas of AAV tropism in the mouse
Walkey, C. J., Snow, K. J., Bulcha, J., Cox, A. R., Martinez, A. E., Ljungberg, M. C., Lanza, D. G., Giorgi, M. D., Chuecos, M. A., Alves‐Bezerra, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.041 · Cited by 68
Słyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“This may lead to a stronger adaptive response in AAV gene therapy in females with greater cell and antibody-mediated immunity directed against the transgene product resulting in poorer treatment durability (Piechnik et al., 2022).”
Giles, A. R., Lock, M. W., Chen, S., Turner, K. B., Wesolowski, G. A., Prongay, A., Petkov, B., Olagbegi, K., Yan, H., & Wilson, J. M. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.116 · Cited by 23
“19 Considering the established nature of this phenomenon in the literature, further pursuit of sex-based differences was deemed unnecessary.”
Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age
Clare, A. J., Langer, P. M., Ward, A., Chan, Y. K., Dick, A. D., & Copland, D. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.028 · Cited by 19
Notarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 21
“61 This suggests that sex plays an important role in therapeutic efficacy.”
BackgroundAn Nrf2-NF-κB Crosstalk Controls Hepatocyte Proliferation in the Normal and Injured Liver
Kuklin, A., Slabber, C. F., Tortola, L., Kwan, C. L., Liebisch, G., Kondylis, V., Mair, F., Köpf, M., Weber, A., & Werner, S. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101480 · Cited by 15
“30,31 To validate the protocol, we injected AAV8Cre into Rosa26-tdTomato reporter mice, in which expression of tdTomato is dependent on the presence of Cre.”
de Oliveira, F. A., Tokuhara, C. K., Mohamed, F. F., Narisawa, S., dos Santos, E. J. L., Andras, N. L., Shadid, M., Miyake, K., Foster, B. L., & Millán, J. L. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf005 · Cited by 11
Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer
Laurent, M., Harb, R., Jenny, C., Oustelandt, J., Jimenez, S., Cosette, J., Landini, F., Ferrante, A., Corre, G., Vujić, N., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00816-8 · Cited by 13
McMurphy, T. B., Park, A., Heizer, P. J., Bottenfield, C., Kurasawa, J. H., Ikeda, Y., & Doran, M. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-75698-2 · Cited by 11
“Similarly, Piechnik et al., reported significantly greater transduction of heart, kidney, lung, spleen, and bone tissues in male versus female mice when using AAV8 49 .”
Rintz, E., Çelik, B., Nidhi, F., Herreño-Pachón, A. M., Khan, S. A., Benincore-Flórez, E., & Tomatsu, S. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102211 · Cited by 9
“Based on our previous results, 31 we anticipated an increase in antibody levels throughout the weeks of the experiment, peaking around the fi nal weeks.”
Self-citationKhan, S. A., Álvarez, J. V., Nidhi, F., Benincore-Flórez, E., & Tomatsu, S. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101447 · Cited by 12
“19,21 peripheral tissues and successive improvement in skeletal and non-skeletal lesions.”
Self-citationSmith, M. C., Belur, L. R., Karlen, A. D., Erlanson, O., Furcich, J. W., Lund, T. C., Seelig, D. M., Kitto, K. F., Fairbanks, C. A., Kim, K. H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101201 · Cited by 9
Belur, L. R., Huber, A. K., Mantone, H., Robertson, M., Smith, M. C., Karlen, A. D., Kitto, K. F., Ou, L., Whitley, C. B., Braunlin, E., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101369 · Cited by 7
“51 – 54 A systematic evaluation of the in fl uence of sex on transduction by recombinant AAV2 (rAAV2) indicated that transgene expression after liver-targeted delivery of vector particles was between 5-to 13-fold higher in male mice compared with female mice, irrespective of the promoter, cDNA, or…”
Wiśniewska, K., Rintz, E., Żabińska, M., Gaffke, L., Podlacha, M., Cyske, Z., Węgrzyn, G., & Pierzynowska, K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150718 · Cited by 5
Herreño-Pachón, A. M., Sawamoto, K., Stapleton, M., Khan, S. A., Piechnik, M., Álvarez, J. V., & Tomatsu, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.096 · Cited by 6
“44 In this study, we tested a higher dose (2.0 · 10 14 GC/kg) of AAV vectors expressing hGALNS, with or without a bone-targeting signal, controlled by a liver-speci fi c TBG promoter.”
InfluentialSelf-citationAbdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 7
Opportunities and Challenges of Fetal Gene Therapy
Jeanne, M., & Chung, W. K. (2025) · Prenatal Diagnosis · doi:10.1002/pd.6809 · Cited by 6
“This immunological advantage may also be beneficial for disorders such as lysosomal storage diseases since immune responses to enzyme replacement therapy in patients without endogenous protein can limit efficacy and require long‐term immunosuppression [21, 22].”
Recent advances in mucopolysaccharidosis IVA treatment
Leal, A. F., & Pachajoa, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04028-0 · Cited by 6
“To assess the influence of sex on the presence of anti-hGALNS neutralizing Abs and GT efficacy, Piech-nik et al.. (2022) treated young male and female MPS IVA mice with AAV8 vectors carrying TGB-GALNS cDNA under the control of TGB and the ubiquitous promoter CAG [60].”
InfluentialLong-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA
Khan, S. A., Benincore-Flórez, E., Nidhi, F., Álvarez, J. V., Holder, D. A., & Tomatsu, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110900 · Cited by 5
“Sex hormones are important modulators of immunity; estrogens are potent enhancers of humoral immunity, promoting B-cell activation and antibody production, while androgens, such as testosterone, are generally considered immunosuppressive [65].”
Self-citationÇelik, B., Leal, A. F., Khan, S. A., & Tomatsu, S. (2025) · Journal of Human Genetics · doi:10.1038/s10038-025-01353-x · Cited by 1
Self-citationHamann, V., Hook, S., Sujariyakul, P., Ramalingam, R., Sgodda, M., Klefenz, I., Stalke, A., Yuan, Q., Steinbrück, L., Rovai, A., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.05.022 · Cited by 1
Gender difference in pre-clinical liver-directed gene therapy with lentiviral vectors
Guzman, E., Khoo, C. P., O’Connor, D., Devarajan, G., Iqball, S., Souberbielle, B. E., Mitrophanous, K. A., & Lad, Y. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10422 · Cited by 1
Integrated AAV optimization enables efficient gene delivery to kidney in murine and human tissuePreprint
García, F. G., Moreno, M. R., Chetty, S. S., Johnson, N. S., An, A., Sostena, J., Thompson, L. M., Wang, J., Charu, V., Lee, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7925411/v1 · Cited by 1
“32,33 Due to the estrogen hormone, females tend to mount a more robust immune response to AAV with higher levels of neutralizing antibodies and cytokine/chemokine activity.”
AAV9-mediated gene therapy restores liver function in the MEGDHEL mouse model
Wei, T., Lin, Y., Ouyang, W., Yu, L., Yang, X., Chen, L., He, X., Fang, Q., Zheng, X., Tong, H., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120014
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244 · Cited by 2
“50 In a U.S.-based analysis, females were reported to have higher pre-existing anti-AAV Ab levels, including NAb activities against a selection of AAV serotypes, and AAV dose-dependent differences in in fl ammatory response between males and females suggest that enhanced immune response in females…”
Gong, W., Jiang, H., & Qu, Y. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.04.006
Watanabe, N., Kawahori, Y., Ta, V., Wang, D., Ohgi, K. A., Wang, H., Kleschevnikova, N., Ishikawa, E., & Head, B. P. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201820 · Cited by 1
“34 Ultimately, these findings under-score the critical importance of analyzing sex as a biological variable, revealing that robust vector delivery does not universally equate to superior therapeutic efficacy across both sexes.”
Metadata
- Authors
- Piechnik, M., Amendum, P. C., Sawamoto, K., Stapleton, M., Khan, S., Fnu, N., Álvarez, V., Pachon, A. M. H., Danos, O., Bruder, J. T., Karumuthil-Melethil, S., & Tomatsu, S.
- Affiliations
- Alfred I. duPont Hospital for Children (US)
- Philadelphia College of Osteopathic Medicine (US)
- Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE 19803, USA
- Regenxbio (United States) (US)
- REGENXBIO Inc., Rockville, MD 20850, USA
- Corresponding author
- Tomatsu, Shunji
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-21
- Volume
- 23
- Issue
- 20
- Pages
- 12693
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9604118
- OpenAlex
- W4307263165
- Cited by
- 28
- References
- 64
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 7 · 2023: 2
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Austrian MPS society (1R01HD102545-01A1)
- A Cure for Robert, Inc (1R01HD102545-01A1)
- The Carol Ann Foundation (1R01HD102545-01A1)
- Angelo R. Cali & Mary V. Cali Family Foundation, Inc. (1R01HD102545-01A1)
- The Vain and Harry Fish Foundation, Inc. (1R01HD102545-01A1)
- The Bennett Foundation (1R01HD102545-01A1)
- Jacob Randall Foundation (1R01HD102545-01A1)
- Nemours Funds (1R01HD102545-01A1)
- Institutional Development Award from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NICHD) (1R01HD102545-01A1)
- REGENXBIO Inc. (1R01HD102545-01A1)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mucopolysaccharidosis IVA, AAV8 gene therapy, sex differences, neutralizing antibodies, GALNS, N-acetylgalactosamine-6-sulfate sulfatase, lysosomal storage disease, articular cartilage, treatment efficacy
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Animals, Chondroitinsulfatases, Disease Models, Animal, Female, Humans, Male, Mucopolysaccharidoses, Mucopolysaccharidosis IV, Sex Characteristics, Genetic Therapy, Gene Expression, Capsid Proteins, Isovaleryl-CoA Dehydrogenase, Mice, Thyroxine-Binding Globulin, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.